We evaluated the effects of 12-month treatment with sibutramine 15 mg daily compared with placebo on healthrelated quality of life (HRQL) in obese type II diabetes patients. We examined the associations between the changes in HRQL and in weight, glycaemic control, and haemodynamic variables. We also explored the predictive value of HRQL and its changes early during treatment. DESIGN: A randomised clinical trial. The subjects were enrolled in a 2-week single-blind run-in period with a modestly hypocaloric diet (700 kcal daily deficit) and then randomised to receive either sibutramine 15 mg (n ¼ 114, 60% female) or placebo (n ¼ 122, 58% female) once daily with the hypocaloric diet for 12 months. SUBJECTS: Obese (mean BMI 36 kg/m 2 and age 54 y) type II diabetes patients untreated with antidiabetic medications. MEASUREMENTS: The main outcome measures included body weight and HRQL (the RAND 36-Item Health Survey 1.0). RESULTS: The mean weight loss was greater in the sibutramine group (À7.1 kg) than in the placebo group (À2.6 kg, Po0.001). The baseline HRQL was relatively high. There were no significant differences between the treatment groups in glycaemic control or in any of the RAND-36 scales during the study. The scores on physical functioning (PF) and health change (HC) since last year improved in both groups and this improvement was related to weight loss. When HRQL changes were examined in categories of weight loss, the scores on PF and HC increased with Z5% weight loss, but the scores on vitality (V) and general health (GH) increased only after Z15% weight loss. Decrease in HbA1c was associated with increases in the scores of PF, GH, V, mental health, and HC. In the sibutramine group, the increase in diastolic blood pressure was associated with the decrease in the scores of PF, physical role functioning, emotional role functioning (ERF), social functioning (SF), and bodily pain. High baseline scores on ERF and SF, and low scores on V predicted weight loss at 12 months. Also, increasing scores on PF and V during the first 3 months predicted weight loss at 12 months. The sum of four dichotomised HRQL variables (baseline ERF Z75 ¼ 1 and o75 ¼ 0; baseline SFZ80 ¼ 1 and o80 ¼ 0; 3-month change in PF40 ¼ 1 and r0 ¼ 0; 3-month change in V40 ¼ 1 and r0 ¼ 0) predicted weight loss: In the group with sum 0, the mean(s.d.) weight change at 12 months was 0.0(2.6)% and with sum 4 it was -9.0(8.1)% of baseline weight. CONCLUSION: Despite the superior weight loss, sibutramine 15 mg daily did not produce HRQL benefits over placebo when measured with the generic RAND-36 in obese type II diabetes patients. PF and HC since last year improved with Z5% weight loss, but Z15% weight loss was needed to achieve a cluster of HRQL improvements. The decrease in HbA1c was associated with many HRQL benefits. Poor baseline HRQL and the improvement observed in the first months of treatment may prove to be useful in predicting success in long-term weight loss.
Introduction
In observational studies, an increasing degree of obesity has been associated with compromised health-related quality of life (HRQL), especially physical functioning (PF). [1] [2] [3] Weight loss achieved by surgical techniques 1 and lifestyle interventions [4] [5] [6] [7] [8] [9] [10] [11] has improved HRQL. Diabetes with its complications has been associated with deteriorated HRQL [12] [13] [14] [15] [16] and improvement in glycaemic control with the loss of hyperglycaemic symptoms has improved HRQL in type II diabetes patients. 17 Sibutramine, a norepinephrine and serotonin reuptake inhibitor enhances satiety 18, 19 and results in sustained weight loss in obese patients. [20] [21] [22] [23] [24] [25] [26] [27] The aim of this randomised 12-month trial was to examine the effects of sibutramine 15 mg vs placebo on HRQL among obese patients with type II diabetes treated with hypocaloric diet for 12 months.
Subjects and methods

Subjects
Obese (BMI Z28 kg/m 2 ) type II diabetes patients (1985 WHO criteria) aged 25-70 y were recruited at 11 Finnish primary medical care centres. The median time since the diagnosis was about 2 y. The subjects were eligible for the study if treated by diet alone, had a relatively stable weight (o5 kg weight change in previous 3 months), and had no nephropathy, proliferative retinopathy, exudative maculopathy, or insulin deficiency (ketonuria or fasting C-peptide o0.3 mmol/l). Significant illnesses such as uncontrolled hypertension, uncompensated heart failure, symptomatic coronary disease, and renal or hepatic failure led to exclusion. Subjects with medications possibly affecting body weight and women of childbearing potential not taking adequate contraception were also excluded. After an extensive prescreening involving thousands of patients, we screened well over 700 patients with suspect or known diabetes at entry. The baseline characteristics of the study subjects in the two treatment groups (TGs) were similar ( Table 1) . The trial conformed to the Declaration of Helsinki and the ethics committees of all centres approved the study. All subjects gave written informed consent.
Study design
After a 2-week, single-blind, placebo run-in period with a hypocaloric diet (700 kcal daily deficit), the eligible patients were randomised to receive either one capsule of sibutramine 15 mg daily (TG) or placebo once daily (placebo group, PG) for 12 months. During the double-blind period, the patients visited the clinic once a month. After baseline measurements, weight, pulse, and supine blood pressure were measured monthly and fasting plasma glucose and HbA1c were determined at 3-month intervals.
The hypocaloric diet was continued and reinforced throughout the trial for all patients. Advice with regard to diet and compliance with study medication was reinforced during the monthly visits. The subject was withdrawn in case of failure to take study medication for 7 consecutive days or in the event of clinical deterioration, unacceptable adverse events, or protocol violation. The patients were to be withdrawn if diastolic blood pressure (BP) exceeded 105 mmHg or the dose of antihypertensive medication was increased. Antidiabetic medication had to be started if the fasting plasma glucose exceeded 12.0 mmol/l on at least two consecutive measurements. The recommended practice was to start metformin if normoglycaemia was not reached by 3-6 months of the trial.
HRQL measurement
The RAND-36 28 covers separate scales on the physical HRQL:
PF, physical role functioning, bodily pain, and general health (GH); the mental HRQL: mental health, emotional role functioning (ERF), vitality, and social functioning (SF). Each scale has a score range from 0 (maximal impairment) to 100 (no impairment). Also included is a scale on health change (HC) since last year (5-point scale from much worse to much better). The RAND-36 was administered at baseline and at 3, 6, 9, and 12 months during the study. We used the Finnish version of RAND-36 with the population reference values available. 29 
Statistical analysis
Analyses were carried out in the completers' population and in the intent-to-treat (ITT) population, where the end point was defined as the patient's last visit before either withdrawal or completion. The general linear modelling, repeated measure procedure with one factor for comparisons between subjects (sibutramine or PG) and one factor for comparisons within subjects (time with five levels), examined the changes in RAND-36 scores during the study. We defined the comparisons within subjects using the repeated factor to compare each follow-up point to the baseline, in this case four follow-up visits at 3-month intervals.
Bivariate correlation examined the associations between the changes in weight, HRQL scores, HbA1c, and the haemodynamic variables (pulse and blood pressure).
Stepwise backward multiple regression examined the models with predictive value of baseline HRQL and early changes in HRQL with rapid weight loss (first 3 months) on weight loss at 12 months. The sum of four dichotomised HRQL variables determined the clustering of the selected variables. One-way ANOVA examined the weight loss differences between these clusters.
Statistical significance was based at the 5% level. We report the results in the ITT population (the results were similar in the completer population), except for the predictive analyses, where only results in the completers' population are reported. Weight loss and HRQL in obese diabetes patients JK Kaukua et al
Results
Participation
There were three and one early withdrawals in sibutramine and PGs, respectively. Among the remaining ITT population (n ¼ 232), a total of 102 patients on sibutramine (92%) and 108 patients on placebo (89%) completed the study. Table 2 presents the scores on RAND-36 in the study groups at the time of randomisation and in the Finnish general population without chronic diseases. The lowest mean scores in the study population were on vitality and GH. The greatest difference to general population was on the scores of PF. Over 5-point differences between the study population and the general population can be interpreted as significant. 30 Changes in weight, glycaemic control, and haemodynamic variables The patients on sibutramine lost a mean of 7.1 kg (7.3%) of baseline body weight compared with 2.6 kg (2.4%) for placebo (Po0.001). There was no significant change in the glycaemic control in either study group during the trial (À0.2 to 0.3%, % for HbA1c). The mean change in systolic blood pressure was 4.1 mmHg in the sibutramine group and 3.6 mmHg in the PG (P ¼ 0.81). The mean change in diastolic BP was, respectively, 1.7 and -0.2 mmHg in the sibutramine and PGs (P ¼ 0.06). The mean increase in pulse rate in the sibutramine group was 5.5 beats/min compared with 1.3 beats/min in the PG (Po0.001).
Changes in HRQL
The scores on PF and HC since last year increased in both groups during the study (Figure 1 ), but there were no statistically significant differences between SG and PG. The weight loss at 12 months (% of baseline weight) was correlated with the increase in the scores of PF (r ¼ 0.187, P ¼ 0.005) and HC since last year (r ¼ 0.260, Po0.001). None of the other scales on RAND-36 showed statistically significant changes nor between group differences during the study (unadjusted and adjusted for weight loss).
For patients with poor glycaemic control at baseline (HbA1c Z8%), there were no statistically significant differences between the groups in any of the RAND-36 scales (data not shown).
When both groups were pooled together, the change in HbA1c at 12 months correlated inversely with the changes in the scores of PF (r ¼ À0.149, P ¼ 0.035), vitality (À0.210, o0.001), mental health (À0.154, 0.026), GH (À0.137, 0.048), and HC since last year (À0.165, 0.017).
In the sibutramine group the change in diastolic blood pressure was inversely associated with the changes in scores of PF (r ¼ À0. Weight loss and HRQL in obese diabetes patients JK Kaukua et al
HRQL changes in categories of weight loss
The changes in HRQL during 12 months were examined in the categories of weight loss with 5% intervals (Figure 2 ). The change in HRQL was considered clinically significant if the median change was Z5 points. There was a clinically significant increase in the scores of PF and HC since last year with Z5% weight loss, but Z15% weight loss was needed to increase vitality. The score on GH increased with both weight gain (median 5 points) and with Z15% weight loss (median 12.5 points). We chose the four predictive HRQL scales with positive correlation to weight loss at 12 months, dichotomised these variables with clinically meaningful cutoff points (baseline ERF Z75 ¼ 1 and o75 ¼ 0; baseline SF Z80 ¼ 1 and o80 ¼ 0; 3-month change in PF 40 ¼ 1 and r0 ¼ 0; 3-month change in vitality 40 ¼ 1 and r0 ¼ 0) and computed the sum of these dichotomised HRQL variables. This cluster predicted weight loss; the mean weight reduction at 12 months increased linearly with increasing cluster. In the group with sum 0, the mean (s.d.) weight change was þ 0.0(2.6)%, (1) À2.6(5.2)%, (2) -3.7(4.7)%, (3) -6.1(5.4)%, and (4) 
HRQL as a predictor of weight loss maintenance
Discussion
This randomised controlled 12-month weight loss trial among obese type II diabetes patients showed that despite the substantially greater weight loss, sibutramine did not produce HRQL benefits over placebo when measured with the generic RAND-36. However, even modest weight loss of Z5% improved PF (eg ability to perform daily tasks and activities such as walking, climbing stairs, or carrying groceries) and HC since last year (eg range from much worse to much better). Much larger (Z15%) weight loss was needed to improve GH (eg getting sick more easily than others, expecting worse health in the future), and vitality (eg range from worn out to feeling full of life, from feeling tired to having a lot of energy), the HRQL domains with the lowest scores at baseline.
The improvement in glycaemic control was associated with slight improvement in PF, vitality, mental health (eg amount of time with feelings ranging form nervous to calm and low mood to happy), GH, and HC since last year. In the SG, increase in diastolic blood pressure was associated with negative changes in HRQL.
In this study, good ERF (eg problems with work or other daily activities due to any emotional problems), good SF (eg health problems interfering with social activities with family, friends, neighbours, and groups), and poor vitality at baseline predicted weight loss at 12 months. Not only baseline characteristics but also benefits achieved with weight loss may predict long-term success. In this study, the improve- Weight loss and HRQL in obese diabetes patients JK Kaukua et al ments in PF and vitality during the initial 3-month weight loss phase predicted weight loss result at 12 months. When these predictors were combined in the cluster analysis, it was evident that subjects with good ERF and good SF at baseline and improvement in PF and vitality during the first 3 months achieved the largest maintained weight loss.
Observational studies have shown an association between obesity and impaired PF, [1] [2] [3] but the association with mental functioning has been more diverse. Morbidly obese patients, 31 and obese patients suffering from comorbidity, 32 binge eating, 33 or pain 34 have reported deteriorated mental well-being. Previous randomised weight loss trials 6, 7 with lifestyle intervention have shown improvement in PF, physical role functioning, GH, vitality, SF, and mental health. These studies were short in duration (12-13 weeks), had an unequal sex distribution favouring women, measured HRQL during active weight loss, and did not include a weight maintenance phase. One randomised study among obese men losing weight with very-low-energy diet and behaviour modification showed transient improvement in many domains of HRQL during the marked weight loss with the diet, but only improvements in PF, SF, and obesityrelated psychosocial problems were maintained at the end of nearly 6 months into weight maintenance phase. 10 Another study with similar weight loss programme (but a 2-y followup) showed that HRQL benefits were dependent on the success in maintaining the weight loss result. 11 A 10%
weight loss at 2 y after treatment was associated with clear improvement in obesity-related psychosocial problems, PF, physical role functioning, bodily pain, GH, mental health, and vitality. Weight gain was associated with the improvement in obesity-related psychosocial problems and SF. In the present study, weight gain was associated with increased scores in GH. Therefore, it appears that factors other than weight loss per se influence the way the patients rate their HRQL. Studies examining the associations with type II diabetes and HRQL are scarce. In cross-sectional studies, 35, 36 glycaemic control has been associated with HRQL measured by diabetes-specific questionnaires, but not with the generic SF-36 which is nearly identical to RAND-36. However, diabetic complications (especially macrovascular diseases) and other comorbid illnesses seem to deteriorate HRQL measured by SF-36 among type II diabetes patients. [12] [13] [14] [15] [16] [17] One randomised intervention study showed that regular phone contacts with the patients improved glycaemic control but did not induce any improvement in HRQL measured by SF-36. 36 Another study showed that by achieving good glycaemic control (HbA1c from 10.4 to 7.8% during 1 y follow-up) and by losing hyperglycaemic symptoms, the patients gained HRQL benefits especially in PF, vitality, and HC since last year. 37 There are limitations to this study. Despite a specific study population comprising obese type II diabetes patients, the HRQL scores at baseline were on some scales even better than in the Finns with no chronic diseases. This may be due to strict inclusion criteria, relatively good metabolic control, and no significant diabetic complications at baseline. Compared to another intervention trial (17) with type II diabetes patients in poor metabolic control at baseline (mean HbA1c 10.4%) our patients scored higher (Z5 points) on several RAND-36 scales, namely PF, physical role functioning, ERF, mental health, and especially vitality. This, too, indicates that the baseline HRQL was relatively good among our patients. This may lead to ceiling effects or to nonrepresentativeness of the study population.
The patients filled in the questionnaires for the first time after the 2-week run-in period; therefore, we cannot examine the possible HRQL effects of weight loss during the first 2 weeks in the study. In addition, obesity-and diabetes-specific HRQL questionnaires more sensitive to changes in weight and/or glycaemic control than the general measure used here might have revealed clinically important HRQL effects of sibutramine and/or weight loss.
We conclude that obese type II diabetes patients achieved HRQL improvements with intentional weight loss. The ability to perform daily tasks requiring physical activity and subjective perception of own health compared to the situation 1 y ago improved with modest (5-10%) weight loss. Improvement in glycaemic control was weakly associated with the improvement in PF, GH, vitality, mental health, and HC since last year. HRQL measurement may also prove to be useful in predicting long-term treatment success. In this study, the best mean weight loss at 12 months was among those who at baseline had no emotional problems interfering with daily activities and no health problems interfering with social activities and who with weight loss achieved improved physical ability to perform daily activities and felt more full of life and having more energy.
